IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.

GlobeNewswire09-03

LOS ANGELES, Sept. 03, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2464712870?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bYQvcxcJKxZ9Naw2pZUDDw--~B/aD03MTg7dz0xMjc2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/a114a7e9ffad10fc4632c57f21bec6a2","is_english":true,"pubTime":"2024-09-03 20:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2464712870","market":"us","top_or_hot":-1,"title":"IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.","media":"GlobeNewswire","content":"<div>\n<p>LOS ANGELES, Sept. 03, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the...</p>\n\n<a href=\"https://finance.yahoo.com/news/ibn-announces-latest-episode-biomedwire-120000084.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-03 20:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ibn-announces-latest-episode-biomedwire-120000084.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>LOS ANGELES, Sept. 03, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the...</p>\n\n<a href=\"https://finance.yahoo.com/news/ibn-announces-latest-episode-biomedwire-120000084.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DBP","symbol_name":"Invesco DB Precious Metals Fund","start_time":0,"source_url":"https://finance.yahoo.com/news/ibn-announces-latest-episode-biomedwire-120000084.html","article_id":"2464712870","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bYQvcxcJKxZ9Naw2pZUDDw--~B/aD03MTg7dz0xMjc2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/a114a7e9ffad10fc4632c57f21bec6a2"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2464712870","pubTimestamp":1725364800,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"LOS ANGELES, Sept. 03, 2024  -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode ofThe BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.The BioMedWire Podcast features fast-paced interviews with experts guiding the next wave of pharmaceutical and biotech innovation. The latest episode features John Climaco, CEO of CNS Pharmaceuticals Inc. , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system.To begin the interview, Climaco discussed CNS Pharmaceuticals’ business model, including the company’s recent announcement of an exclusive in-license agreement to expand its development pipeline.The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"DBP":"Invesco DB Precious Metals Fund","BK4535":"淡马锡持仓","LU1102505762.USD":"富达新兴市场焦点 A","BK4007":"制药","CNS":"科恩-斯蒂尔斯金融","LU1868838027.USD":"CT (LUX) I GLOBAL EMERGING MARKET EQUITIES \"8\" (USD) ACC","BK4588":"碎股","LU0264410563.USD":"SCHRODER ISF INDIAN EQUITY \"A\" ACC","LU0143863784.USD":"CT (LUX) I GLOBAL EMERGING MARKET EQUITIES\"DU\" (USD) ACC","BK4207":"综合性银行","LU1868837565.USD":"CT (LUX) I GLOBAL EMERGING MARKET EQUITIES \"1\" (USD) ACC","LU0823039010.USD":"AMUNDI FUNDS ASIA EQUITY FOCUS  \"A2\" (USD) INC","CNSP":"CNS Pharmaceuticals, Inc.","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","IBN":"印度工业信贷投资银行","LU0143863198.USD":"CT (LUX) I GLOBAL EMERGING MARKET EQUITIES\"AU\" (USD) ACC","BK4548":"巴美列捷福持仓","IE00B7N09G41.SGD":"柏瑞印度股票A5CP SGD","LU0066902890.USD":"HSBC GIF INDIAN EQUITY \"AD\" (USD) INC","IE00BYTNYM70.SGD":"PINEBRIDGE INDIA EQUITY \"A5\" (SGD) ACC","LU1868837722.USD":"CT (LUX) I GLOBAL EMERGING MARKET EQUITIES \"2\" (USD) ACC","LU0181495838.USD":"施罗德新兴亚洲A Acc","IE00B0JY6M65.USD":"PINEBRIDGE INDIA EQUITY \"A\" (USD) ACC","LU0828237940.HKD":"SCHRODER ISF EMERGING ASIA \"A\" (HKD) ACC","BK4135":"资产管理与托管银行","LU0164881194.USD":"HSBC GIF INDIAN EQUITY \"AC\" (USD) ACC","BK4523":"印度概念","BK4585":"ETF&股票定投概念","LU0823038988.USD":"AMUNDI FUNDS ASIA EQUITY FOCUS  \"A2\" (USD) ACC","LU0531971678.HKD":"HSBC GIF INDIAN EQUITY \"AD\" (HKD) INC","LU0251143458.SGD":"Fidelity Emerging Markets A-SGD"},"translate_title":"IBN宣布BioMedWire播客的最新一集，由CNS制药公司首席执行官John Climaco主讲。","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBN":1,"CNS":1,"DBP":1,"CNSP":0.9},"content_text":"LOS ANGELES, Sept. 03, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.\nThe BioMedWire Podcast features fast-paced interviews with experts guiding the next wave of pharmaceutical and biotech innovation. The latest episode features John Climaco, CEO of CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system.\nTo begin the interview, Climaco discussed CNS Pharmaceuticals’ business model, including the company’s recent announcement of an exclusive in-license agreement to expand its development pipeline.\n“We are an oncology drug development company. Specifically, our space is neuro-oncology – cancers of the brain and the central nervous system. Traditionally, these are some of the most difficult and deadly cancers,” he said. “They are very challenging to treat, because they lie beyond the blood-brain barrier, which is this very specialized network of cells that protects the most important organ in the body. It's very hard to get drugs and treatments to the brain when you have tumors growing in it, so that is really what we specialize in.”\n“We have a very exciting compound called Berubicin. It's a first-in-class drug that penetrates the blood-brain barrier and treats brain cancer. This is in a late stage, designed to be pivotal trial, with over 250 patients in the United States and Europe currently enrolled. It'll be reading top-line data in the first half of next year, so we're very excited about that. We've been working on Berubicin since the company's inception back in 2017.”\n“Our recent news is equally exciting. After many years of searching and diligence and evaluating over 200 different compounds for potential in-license, we settled on an amazing drug called TPI-287, which is a novel abeotaxane of the taxane family. This is also a unique blood-brain barrier penetrant drug that was specifically designed to treat these very difficult brain cancers, such as glioblastoma. This drug has already been used in 350 patients in a series of phase one studies. We are just getting started on planning what will be another designed to be pivotal study for this very exciting drug.”\nJoin IBN’s Carmel Fisher and John Climaco, CEO of CNS Pharmaceuticals Inc., to learn more about what sets Berubicin, as well as the company’s new TPI-287 candidate, apart from anything else in development for glioblastoma.\nTo hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com\nThe latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.\nTo learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine\nAbout CNS Pharmaceuticals Inc.\nCNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.\nFor more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook and LinkedIn.\nAbout IBN\nIBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.\nThrough our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.\nFor more information, please visit https://www.InvestorBrandNetwork.com\nPlease see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer\nForward-Looking Statements\nThis release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.\nCorporate Communications\nIBNLos Angeles, Californiawww.InvestorBrandNetwork.com310.299.1717 OfficeEditor@InvestorBrandNetwork.com","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2464712870"}